Search by First Name and/or Last Name. Results are displayed in descending publication year and then sorted ascending by the reference field. Need to submit a publication reference?
Name: David Holtzman
Year: 2013
Reference:
Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013 Apr 19;8(1):13. PMCID: PMC3640999
Name: David Holtzman
Year: 2013
Reference:
Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”. Science. 2013 May 24;340(6135):924-f. doi: 10.1126/science.1235505.
Name: David Holtzman
Year: 2013
Reference:
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A. 2013 2013 May 7:110(19):E1807-16. PMCID: PMC3651443
Name: David Holtzman
Year: 2013
Reference:
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A. 2013 Apr 25. [Epub ahead of print]
PMID: 23620513
Name: Nigel Cairns
Year: 2013
Reference:
Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM.Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study.Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.PMID:24012374
Name: Anne Fagan
Year: 2013
Reference:
Vos SJB, Xiong C, Visser PJ, Jasielec M, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM, Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study, Lancet Neurology, in press
Name: Anne Fagan
Year: 2013
Reference:
Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, Benzinger TL, Holtzman DM, Morris JC, Ances BM. Cerebrospinal Fluid Aβ42, Phosphorylated Tau181, and Resting-State Functional Connectivity. JAMA Neurol. 2013 Aug 19. doi: 10.1001/jamaneurol.2013.3253. [Epub ahead of print] PMID: 23959173 [PubMed – as supplied by publisher]
Name: Nigel Cairns
Year: 2013
Reference:
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception.Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. PMID:23932184
Name: Anne Fagan
Year: 2013
Reference:
Winer L, Srinivasan D, Chun S, Lacomis D, Jaffa M, Fagan A, Holtzman DM, Wancewicz E, Bennett CF, Bowser R, Cudkowicz M, Miller TM. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013 Feb;70(2):201-7. Doi 10.1001/jamaneurol.2013.593. PMID: 23147550 [PubMed – indexed for MEDLINE]
Name: Alison Goate
Year: 2013
Reference:
Zou F, Belbin O, Carrasquillo MM, Culley OJ, Hunter TA, Ma L, Bisceglio GD, Allen M, Dickson DW, Graff-Radford NR, Petersen RC; Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium, Morgan K, Younkin SG. Linking protective GAB2 variants, increased cortical GAB2 expression and decreased Alzheimer’s disease pathology. PLoS One 2013: 8(5):e64802. PMCID: PMC3665686
Name: Beau Ances
Year: 2012
Reference:
Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol. 2012 Jan;69(1):72-7. PMCID: PMC3536500.
Name: Anne Fagan
Year: 2012
Reference:
Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Archives of Neurology, 2012 Jan;69: 72-7. PMCID: PMC3536500
Name: Anne Fagan
Year: 2012
Reference:
Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, Teshome M, Aldea P, Fagan AM, Holtzman DM, Morris JC, Clifford DB. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Archives of Neurology, 2012 Jan;69: 72-7. PMCID:PMC3536500
Name: Beau Ances
Year: 2012
Reference:
Ances, B.M., Benzinger, T.L., Christensen, J.J., Thomas, J., Venkat, R., Teshome, M., Aldea, P., Fagan, A.M., Holtzman D.M., Morris, J.C., Clifford, D.B. (2012) HIV Associated Neurocognitive Disorder (HAND) is Not Associated with Increased Fibrillar Amyloid Deposits Using 11C-PiB in Middle-Aged HIV+ Participants. Arch Neurol., 69(1):72-7. PMCID: PMC3536500
Name: Nigel Cairns
Year: 2012
Reference:
Armstrong RA, Cairns NJ. Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders. J Neural Transm. 2012 Jun 8. [Epub ahead of print]
PMID: 22678700
Name: Jeffrey Zacks
Year: 2012
Reference:
Bailey, H. R., Zacks, J. M., Hambrick, D. Z., Zacks, R. T., Head, D., Kurby, C. A., & Sargent, J. Q. (in press). Medial temporal lobe volume predicts elders’ everyday memory. Psychological Science.
Name: David Balota
Year: 2012
Reference:
Bangert AS, Abrams RA, Balota DA. Reaching for words and nonwords: Interactive effects of word frequency and stimulus quality on the characteristics of reaching movements. Psychonomic Bulletin & Review 2012; 19(3): 513-520. PMID: 22419404. [PubMed – as supplied by publisher]
Name: David Balota
Year: 2012
Reference:
Bangert AS, Balota DA. Keep up the Pace: Declines in simple repetitive timing differentiates healthy aging from the earliest stages of Alzheimer’s disease. Journal of the International Neuropsychological Society 2012; 18(6): 1052-1063. PMCID: PMC3505757.
Name: Anne Fagan
Year: 2012
Reference:
Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N, Marcus D, Cairns N, Xie X, Blazey T, Holtzman D, Santacruz A, Buckles V, Oliver A, Moulder K, Ghetti B, Klunk W, McDade E, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Schofield P, Sperling R, Salloway S, Morris J and on behalf of the Dominantly Inherited Alzheimer Network (DIAN) Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network). New England Journal of Medicine 2012, Jul 11. PMCID: PMC3474597
Name: Nigel Cairns
Year: 2012
Reference:
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012 Aug 30;367(9):795-804. Epub 2012 Jul 11. Erratum in: N Engl J Med. 2012 Aug 23;367(8):780. PMC3474597
Name: Catherine Roe
Year: 2012
Reference:
Behrens MI, Silva M, Salech F, Merino D, Ponce DP, Sinning M, Xiong C, Roe CM, Quest AFG. Journal of Gerontology: Biological Sciences. (In press).
Name: Anne Fagan
Year: 2012
Reference:
Blennow K, Zetterberg H, Fagan A. Fluid biomarkers in AD. In: Biology of AD, Selkoe D, Holtzman D, Mandelkow E, eds., Cold Spring Harbor Laboratory Press: New York, pgs. 91-113, 2012.
Name: Nigel Cairns
Year: 2012
Reference:
Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development.Alzheimers Dement. 2012 Oct 5. pii: S1552-5260(12)01750-5. PMID:23043900
Name: Nigel Cairns
Year: 2012
Reference:
Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J.Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2012 Oct 5. doi:pii: S1552-5260(12)01750-5. 10.1016/j.jalz.2012.03.002. PMC3542408
Name: Nigel Cairns
Year: 2012
Reference:
Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier).Alzheimers Dement. 2012 Oct 9. pii: S1552-5260(12)01751-7. PMID:23062850